...
首页> 外文期刊>Cardiovascular drugs and therapy >Single-Strand DNA-Like Oligonucleotide Aptamer Against Proprotein Convertase Subtilisin/Kexin 9 Using CE-SELEX: PCSK9 Targeting Selection
【24h】

Single-Strand DNA-Like Oligonucleotide Aptamer Against Proprotein Convertase Subtilisin/Kexin 9 Using CE-SELEX: PCSK9 Targeting Selection

机译:使用CE-SELEX:PCSK9靶向选择的单链DNA样寡核苷酸适体抗proProtein转化酶枯草杆菌蛋白酶/ kexin 9

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background Proprotein convertase subtilisin/kexin 9 (PCSK9) serves a key regulatory function in the metabolism of low-density lipoprotein (LDL)-cholesterol (LDL-C) through interaction with the LDL receptor (LDLR) followed by its destruction that results in the elevation of the plasma levels of LDL-C. The aims of the present study were to separate and select a number of single-stranded DNA (ssDNA) aptamers against PCSK9 from a library pool (n > 10(12)) followed by their characterization. Methods The aptamers obtained from the DNA-PCSK9 complexes which presented the highest affinity against PCSK9 were separated and selected using capillary electrophoresis evolution of ligands by exponential enrichment (CE-SELEX). The selected aptamers were amplified and cloned into a T/A vector. The plasmids from the positive clones were extracted and sequenced. The Mfold web server was used to predict the secondary structure of the aptamers. Results Following three rounds of CE-SELEX, the identified anti-PCSK9 ssDNA aptamers, namely aptamer 1 (AP-1) and aptamer 2 (AP-2), presented half maximal inhibitory concentrations of 325 and 327 nM, lowest dissociation constants of 294 and 323 nM, and most negative Gibbs free energy values of - 9.17 and - 8.28 kcal/mol, respectively. Conclusion The results indicated that the selected aptamers (AP-1 and AP-2) induced potent inhibitory effects against PCSK9. Further in vivo studies demand to find out AP-1 and AP-2 aptamers as suitable candidates, instead of antibodies, for using in therapeutic purposes in patients with hypercholesterolemia and cardiovascular disease.
机译:背景技术ProProtein转化酶枯草杆菌蛋白酶/ kexin 9(PCSK9)在低密度脂蛋白(LDL)的代谢中,通过与LDL受体(LDLR)的相互作用,然后使其破坏LDL-C等离子体水平的升高。本研究的目的是将许多单链DNA(SSDNA)适体从文库池(N> 10(12))分离,然后选择它们的表征。方法使用指数富集(CE-SELEX)使用配体的毛细管电泳演化分离并选择从呈现对PCSK9最高亲和力的DNA-PCSK9复合物中的适体。将所选的适体扩增并克隆到T / A载体中。从阳性克隆中提取并测序质粒。 MFOLD Web服务器用于预测APTamers的次要结构。结果在三轮CE-SELEX之后,鉴定的抗PCSK9 SSDNA适体,即适体1(AP-1)和适体2(AP-2),呈现了325和327nm的半最大抑制浓度,最低解离常数为294和323nm,以及最负面的gibbs自由能值 - 9.17和-8.28 kcal / mol。结论结果表明,所选适体(AP-1和AP-2)对PCSK9引起有效的抑制作用。进一步在体内研究中,需要发现AP-1和AP-2适体作为合适的候选者,而不是抗体,用于在高胆固醇血症和心血管疾病患者中使用治疗目的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号